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Abstract
Targeting viral vectors to certain tissues in vivo has been a major challenge in gene therapy. Cell type-directed vector
capsids can be selected from random peptide libraries displayed on viral capsids in vitro but so far this system could not
easily be translated to in vivo applications. Using a novel, PCR-based amplification protocol for peptide libraries displayed on
adeno-associated virus (AAV), we selected vectors for optimized transduction of primary tumor cells in vitro. However, these
vectors were not suitable for transduction of the same target cells under in vivo conditions. We therefore performed
selections of AAV peptide libraries in vivo in living animals after intravenous administration using tumor and lung tissue as
prototype targets. Analysis of peptide sequences of AAV clones after several rounds of selection yielded distinct sequence
motifs for both tissues. The selected clones indeed conferred gene expression in the target tissue while gene expression
was undetectable in animals injected with control vectors. However, all of the vectors selected for tumor transduction also
transduced heart tissue and the vectors selected for lung transduction also transduced a number of other tissues,
particularly and invariably the heart. This suggests that modification of the heparin binding motif by target-binding peptide
insertion is necessary but not sufficient to achieve tissue-specific transgene expression. While the approach presented here
does not yield vectors whose expression is confined to one target tissue, it is a useful tool for in vivo tissue transduction
when expression in tissues other than the primary target is uncritical.
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Introduction
Efficient and specific delivery of therapeutic genes to the tissue of
interest is a paramount and so far unsolved issue in gene therapy.
Among the available viral vectors for gene delivery, adeno-
associated virus (AAV) has gained particular attention. The low
frequency of random integration into the genome [1] and the
moderate immune response make AAV an attractive basis for gene
therapy vector design [2,3]. No substantial safety issues have been
encountered in a number of clinical trials involving AAV vectors
[1]. Like in almost all other gene therapy vectors, the tropism of
AAV-2 derived vectors limits its use for the gene transduction of
certain tissues especially when vectors are delivered systemically.
This may partly be circumvented by using AAV serotypes with an in
vivo gene transduction pattern most closely fitting the needs of the
application [4]. Also, the tropism of AAV capsids may be changed
by combining parts of the natural serotype diversity (reviewed in
[5]). Alternatively or in addition, peptides mediating binding to the
cell type of interest can be identified by random phage display
library screening and subsequently be introduced into an AAV
capsid region critical for receptor binding [6,7,8,9,10,11,12]. Such
peptide insertions into or other mutational manipulations of the
heparin binding domain adjacent to VP capsid protein position
R588 can abrogate the natural tropism of AAV-2 capsids to
heparan sulfate proteoglycane (HSPG)-expressing cells and result in
de-targeting from the liver in vivo [13,14,15]. The identification of
numerous tissue-directed peptide ligands during the last decade
[16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32] would seem
to supply almost unlimited potential for the introduction of ligands
into AAV capsids to establish targeted gene delivery in vivo. This
approach has indeed been reported to be successful using certain
peptides [10,11,12]. Yet, our own experience has been, that for
many peptides cell tropism changes or gets lost after inserting them
into the AAV capsid (author’s unpublished observation). This may
be due to a number of reasons. First and foremost, the peptide’s
conformation may change unpredictably when incorporated into
the structural AAV capsid context, leading to a reduced receptor-
ligand affinity and specificity. Further, peptides isolated by phage
display screenings are commonly selected based on receptor binding
but not on subsequent internalization, nuclear transfer, and
transgene expression. To overcome these obstacles, a screening
system based on random peptide libraries displayed directly on
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AAV capsids has recently been developed were the AAV library
particles are amplified based on binding, uptake and viral gene
expression in the target cell via adenoviral helper co-infection
[14,33]. Capsid mutants efficiently transducing various different cell
types have been isolated from such libraries by biopanning on the
cells of interest [14,33,34,35,36,37]. Even though numerous AAV
capsid variants have been isolated by AAV library screenings,
comparative gene expression analyses of such modified AAV
derived vectors have not been performed in vivo and, despite the
obvious importance of the question, it remains open for most of
these vectors whether or not a retargeting after systemic
administration in vivo occurs.
Vector targeting in vivo faces several hurdles which are not
present in vitro and the mechanisms that determine a vectors
tropism and its gene transduction properties in vivo are as yet
poorly understood. While in vivo biodistribution of a vector is to a
considerable part defined by clearance, its gene transduction
properties are rather dependent on receptor binding, cellular
uptake, nuclear transfer, and transgene expression. Thus, major
hurdles for receptor targeted gene transfer in vivo are to improve
specific ligand-receptor interactions under circulation conditions
as well as to overcome host-anti-vector immune reactions, rapid
vector clearance from the circulation by the reticuloendothelial
system, and endothelial cell layers as well as the extracellular
matrix acting as physical barriers [38]. Taking these consider-
ations into account, in vivo biopanning of random AAV peptide
libraries seems to be more appropriate to select for tissue directed
gene vectors than mere tissue culture-based approaches. Among
the limitations faced by in vivo AAV display library selection is the
difficulty to rescue and amplify tissue-targeted library viruses for
multiple selection rounds as the amplification systems used in vitro
are based on adenoviral superinfection and can therefore not
easily be applied in living animals.
In this study, we set out to isolate tissue-directed AAV capsids
using murine breast cancer and lung tissue as prototype targets.
We established a novel adenovirus-free PCR based screening
approach that amplifies tissue-targeted library viruses and
therefore allows for multiple AAV library screening rounds after
systemic application in vivo. We further analyzed gene transduction
properties of the isolated capsid variants. While the selected
vectors indeed transduced their target tissue orders of magnitude
better than unselected vectors, we almost invariably observed
unintended transduction of heart tissue. These results show that
modification of the HSPG-binding capsid domain of AAV vectors
by targeting peptide insertion is necessary but not sufficient to
achieve completely tissue-specific transgene expression while this
technical approach may be appropriate when expansion rather
than restriction of AAV tropism to the tissue of interest is needed.
Our findings therefore broaden the functional understanding of
AAV-2 vectors, particularly when selected from random AAV
display peptide libraries.
Materials and Methods
Cells and cell culture
293T cells (kindly provided by David Baltimore, California
Institute of Technology, Pasadena, CA), were maintained in
Dulbecco’s Modified Eagle’s medium (DMEM; Invitrogen,
Carlsbad, CA) containing 1% penicillin/streptomycin solution
(Invitrogen) and 10% fetal calf serum (FCS; Biochrom, Berlin,
Germany). Primary murine breast cancer cells were obtained from
tumors growing in female transgenic FVB mice expressing the
polyoma middle T antigen under the control of the mouse
mammary tumor virus promoter [39,40] as previously described
[41]. Briefly, tumors were cut into small pieces and digested for
1 h at 37uC in collagenase 2 solution (Biochrom), dissolved in PBS,
10% 2 mMMgCl2/CaCl2 and 10% BSA. The cell suspension was
passed through 100 mm and 40 mm cell strainers, washed twice
with PBS, and cultured in Iscove’s Modified Dulbecco’s Medium
(IMDM; Invitrogen) containing 10% fetal bovine serum, 10%
horse serum, 1% penicillin/streptomycin, and 1.25 mg/ml am-
photericin B (Invitrogen). All cells were cultured in a humidified
atmosphere at 37uC and 5% CO2. Immunodetection using a pan-
cytokeratin antibody (Sigma) revealed more than 95% of
cytokeratin-positive tumor cells after 24 hours in culture.
Animals and tumor staging
All procedures involving animals were performed according to
the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication No. 85-
23, revised 1996) and the German Animal Protection Code. We
used a transgenic breast cancer mouse model induced by the
polyoma middle T antigen (PymT) under control of the mouse
mammary tumor virus promoter. The mouse strain FVB/N-
TgN(MMTVPyVT)634-Mul (PymT) was purchased from Jackson
Laboratory (Bar Harbor, ME). Genotyping was performed by
polymerase chain reaction (PCR) as described by Jackson
Laboratory (www.jax.org). Starting at the age of 30 days,
transgenic female mice were palpated weekly for early detection
of mammary tumors. The animals were anesthetized by
intraperitoneal injection of 100 mg/kg body weight 10% ketamine
hydrochloride (115.34 mg/ml; Essex, Munich, Germany) and
5 mg/kg body weight 2% xylazine hydrochloride (23.32 mg/ml;
Bayer, Leverkusen, Germany).
AAV peptide library biopanning in vitro and in vivo
A random X7 AAV display peptide library (random insert
introduced at position R588 VP1 capsid protein numbering) with
a diversity of 26108 random clones (determined at the cloned
plasmid level) was produced using a three-step protocol as
described previously [14,35]. For in vitro biopanning (Figure 1,
pathway A), 26106 primary PymT breast cancer cells were
incubated with the AAV library at a multiplicity of infection
(MOI) of 1.000 vector genomes (vg)/cell in selection round 1, 500
vg/cell in round 2, and 100 vg/cell in round 3. After 96 hours,
unbound AAV library particles were removed by 3 washing steps
in PBS. Surface-bound library viruses were detached by trypsin
digestion for 20 minutes and subsequent washing. Previous work
had shown that this additional trypsin digest is essential to enrich
internalizing clones for improved transduction of the target cells
(M.T., unpublished observation). Whole cellular DNA was
extracted using the QIAamp Tissue Kit (Qiagen, Hilden,
Germany). The random oligonucleotides contained in AAV
library particles internalized into tumor cells were amplified by
PCR using the primers 59-GGTTCTCATCTTTGGGAAG-
CAAG-39 and 59-TGATGAGAATCTGTGGAGGAG-39. For
in vivo/ex vivo biopanning of AAV peptide libraries (Figure 1,
pathway B), 161010 vg of an AAV library for selection round 1, or
26108 to 26109 vg per animal for round 2–4 were injected into
the tail vein of female PymT transgenic mice bearing palpable
breast tumors. After 24 hours, primary breast cancer cells were
prepared as described above and grown in vitro for 96 hours.
Oligonucleotide inserts of targeted AAV library particles were
amplified by nested PCR using whole cellular DNA as template.
Primers were 59-ATGGCAAGCCACAAGGACGATG-39 and
59- CGTGGAGTACTGTGTGATGAAG-39 for the first PCR
and 59-GGTTCTCATCTTTGGGAAGCAAG-39 as well as 59-
TGATGAGAATCTGTGGAGGAG-39 for the second PCR.
AAV In Vivo Library Panning
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Pure in vivo library biopanning (Figure 1, pathway C) was
performed along the same lines, except that the circulation time
was 48 hours and that DNA extraction from the tumor tissue was
done without prior ex vivo growth of the cells. To select for lung
homing AAV, libraries were injected into the tail vein of 6-week-
old female PycB/FVB wild-type mice (n = 2 animals per selection
round) as described for tumor selections (Figure 1, pathway C).
DNA of whole lung tissue extracts from two animals was extracted,
pooled and used as template to amplify the random oligonucle-
otide of lung-homing AAV. We varied the time of AAV blood
circulation before lung harvest in 2 alternative selection approach-
es (5 minutes followed by a perfusion step, 48 hours in round 1,
48 hours or 6 days for round 2, and 6 days for round 3 to 4). For
all selections, PCR products were analyzed by agarose gel
electrophoresis to verify correct size, digested with BglI and cloned
into the SfiI-digested pMT-202-6 library backbone plasmid
[14,35]. Cloned AAV library plasmids were transformed into
electrocompetent E. coli DH5-a (Invitrogen) using the Gene Pulser
(Bio-Rad, Hercules, CA). Randomly assigned clones were
sequenced using the reverse primer 59-CAGATGGGCCCCT-
GAAGGTA-39. For production of pre-selected AAV peptide
libraries, 26108 293T cells were transfected with the library
plasmids at a ratio of 25 plasmids/cell using Qiagen’s PolyFect
reagent. pUC18 (Invitrogen) served as carrier DNA. Two hours
after transfection, 293T cells were superinfected with wild-type
adenovirus type 5 (Ad5, supplied by the Laboratoire de The´rapie
Ge´nique, Nantes, France) at an MOI of 5 infectious particles/cell
for library particle amplification. After 48 h, or when cell lysis
Figure 1. Pathways used for selection of targeted viral capsids by screening random AAV display peptide libraries. For all selection
pathways, genomic DNA containing cap gene fragments from internalized library viruses was extracted from the target cells or tissue. Library inserts
were amplified by nested PCR and cloned back into the AAV library backbone plasmid pMT-202-6. The resulting pre-selected plasmid library was
used to produce a secondary AAV library by transfection into 293T cells and subsequent superinfection with Ad5. Pre-selected AAV libraries were re-
subjected to selection on the target cells in vitro or the target tissue in vivo. Preceding the amplification step, the library selection was done according
to one of the following three pathways: Pathway A, in vitro selection: A random AAV display peptide library was incubated on primary breast
cancer dissociation cultures derived from female tumor-bearing PymT mice. Non-internalized AAV library particles were removed by extensive
washing followed by trypsin digestion prior to DNA extraction and AAV insert amplification. Pathway B, in vivo/ex vivo selection: A random AAV
display peptide library was injected intravenously into female tumor-bearing PymT mice. After 24 hours, primary tumor cells of the injected mouse
were prepared as in pathway A and grown ex vivo for 96 hours prior to DNA extraction and AAV insert amplification. Pathway C, in vivo selection:
A random AAV display peptide library was injected as in pathway B in tumor-bearing mice (for selection of tumor-homing AAV) or wild-type mice (for
selection of lung homing AAV), respectively. After 48 hours, the target tissue (tumor or lung, respectively) was removed and lysed, and DNA was
extracted for AAV insert amplification.
doi:10.1371/journal.pone.0005122.g001
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became apparent, cells were detached from the culture dish in
PBS-MK (140 mM NaCl, 5.5 mM KCl, 8 mM Na2HPO4,
1.5 mM KH2PO4, 1 mM MgCl2) and pooled with supernatants.
AAV library particles were harvested by cell lysis via three freeze-
thaw cycles. Cellular DNA was removed by incubation with
benzonase (Sigma) at 50 U/ml lysate at 37uC for 30 min, followed
by Ad5 inactivation at 55uC for 30 min. Viral library preparations
were purified using the iodixanol gradient centrifugation method
as previously described [42,43]. The 40% iodixanol fraction
containing the purified AAV viruses was stored at 280uC until
further use.
Production of capsid modified recombinant AAV vectors
Recombinant AAV (rAAV) vectors displaying selected peptide
sequences were generated by cloning the oligonucleotide inserts
into the pXX2-187 plasmid (a derivative of the library backbone
plasmid pMT-187-0-3 without ITRs) [34,35]. 293T packaging
cells were transfected with the modified pXX2-187 (or pXX2 for
wild-type AAV-2 capsid controls), pXX6 [44], and a plasmid
carrying a reporter gene or a toxic transgene of interest using
PolyFect (Qiagen). Packaged reporter genes included the luciferase
(luc) gene in the plasmid pUF2-CMV-luc [34]. The HSV
thymidine kinase mutant SR39 [45] was used as a cytotoxic
suicide gene. Cells were harvested 96 hours after transfection, and
vectors were purified by iodixanol gradient centrifugation as
described above.
AAV titration and evaluation of vector homing and
serum distribution
The AAV capsid titers were determined as described [46] by
ELISA (Progen, Heidelberg, Germany). The genomic titers of
recombinant AAV vectors and AAV libraries were determined by
quantitative PCR using the Absolute SYBR Green fluorescein
master mix (Abgene, Epsom, UK) and the MyiQ cycler (Bio-Rad)
as previously described [47,48]. Vectors were quantified using the
forward primer 59-GGCGGAGTTGTTACGACAT-39 and the
reverse primer 59-GGGACTTTCCTACTTGGCA-39 specific for
the CMV promoter sequence. The genomic titer of AAV libraries
was determined using the forward primer 59-GCAGTATGGTG-
TATCTACCAA-39 and the reverse primer 59-GCCTGGAA-
GAACGCCTTGTGT-39 specific for the AAV cap gene. Real-
time PCR was done in 20 ml with 0.3 mM for each CMV primer,
or 0.4 mM for each AAV primer, respectively, according to the
manufacturer’s protocol (Abgene). For CMV primers, annealing
temperature was 64uC for 15 seconds. For AAV primers,
annealing temperature was 61uC for 30 seconds. Fluorescence
was measured at the end of each annealing phase. A standard
curve for quantification was generated by serial dilutions of the
respective vector plasmid DNA. Calculations were done using
MyIQ analysis software (Bio-Rad). For quantification of vectors
homing to lung tissue, 561010 capsid-modified rAAV-luciferase
vectors were injected into the tail vein of female PycB/FVB wild-
type mice (n = 3 per group). After 8 d, lung tissue was removed.
Whole DNA was extracted using the DNeasy tissue kit (Qiagen)
and quantified using a 2100Pro spectrophotometer (Amersham
Pharmacia Biotech, Uppsala, Sweden). For real-time PCR, 500 ng
of extracted genomic DNA were used as template to amplify
vector specific DNA using CMV primers as described above. To
determine the amount of circulating AAV library or wild-type
viruses in the blood, 161010 vg were injected into the tail vein of
PycB/FVB wild type mice. Blood was obtained at indicated time
points and centrifuged for 2 minutes at 10,000 rpm. Cell-free
serum was diluted 1:100 in ddH2O and used as template for real-
time PCR using AAV specific primer pairs as described above.
Luciferase gene transduction
To analyze luciferase gene transduction in vitro, 26104 cells per well
were seeded in 24-well plates or 56103 cells per well in 96-well plates
and incubated with AAV-luciferase vectors at an MOI of 10,000 vg/
cell for 72 h. For in vivo gene transfer, 561010 vg of rAAV-luciferase
vectors were injected into the tail vein of anesthetized animals. After 8
or 28 days, respectively, the target tissue and representative control
tissues were removed, snap frozen in liquid nitrogen, and stored at
280uC. Frozen tissue samples and cell lysates were homogenized in
reporter lysis buffer (RLB, Promega, Madison, WI) and luciferase
reporter gene activity was determined in a luminometer (Centro LB
960, Berthold Technologies, Bad Wildbad, Germany) using
Promega’s luciferase assay according to the manufacturer’s instruc-
tions. If required, values were normalized to protein levels in each
probe determined by Bradford assay (Bio-Rad).
Suicide gene transfer and toxicity assay
Cells were seeded at 56103 per well in 96-well plates and
transduced with rAAV-SR39 vectors at an MOI of 10,000 vg/cell.
After two cycles of 10 mM ganciclovir (GCV) treatment (24 hours
and 72 hours after transduction), the number of viable cells was
assessed as described [49,50]. Cells were incubated with medium
containing 500 mg/ml MTT (Invitrogen) for 4 h. Subsequently,
absorbance of formazan crystals dissolved in SDS/HCl was
measured at 570 nm in a SpectraMAX microplate reader
(Molecular Devices, Sunnyvale, CA).
Statistics
Statistical analysis was performed using the GraphPad Prism
program 3.0 (GraphPad Software, San Diego, CA). Parametric
data were analyzed by one-way analysis of variance followed by a
Bonferroni post test. Non-parametric data were analyzed by a
Kruskal-Wallis test followed by a Dunn’s post test. p values ,0.05
were considered significant.
Results
PCR-based screening of a random AAV display peptide
library on primary breast cancer cells yields enrichment
of specific peptide motifs
To isolate AAV-2 capsids for targeted gene transfer in primary
breast cancer cells of transgenic PymT mice, we prepared tumor
cells and screened an X7 random AAV display peptide library in
vitro along the lines of pathway A in Figure 1 by which internalized
AAV library particles are amplified based on PCR amplification of
their random oligonucleotide insert. The cap gene region
containing the oligonucleotide insert of AAV recovered from
breast cancer cells after each round of selection was amplified by
nested PCR and correct size of the amplification product was
verified by agarose gel electrophoresis (data not shown). The insert
was cloned back into the library backbone plasmid pMT202-6 and
the diversity of transformed library plasmids was at least 16105
clones for such secondary libraries in this and subsequent
selections (data not shown). New pre-selected AAV particle
libraries were obtained by transfection of 293T cells with the
generated secondary plasmid library in limiting dilution technique
(25 library plasmid molecules per producer cell) to minimize the
production of chimeric AAV library particles or mismatch of
packaged DNA and displayed peptide due to uptake of multiple
library genomes in one producer cell. The titers obtained with this
approach were sufficient for further selection rounds (data not
shown). To increase the stringency of selection, MOIs of AAV
libraries were decreased from 500 vg/cell to 100 vg/cell in rounds
AAV In Vivo Library Panning
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two and three, respectively. Sequence analysis showed enrichment
of several clones after two rounds of selection compared to round
1, functionally validating our novel selection method. Peptide
sequences found after round 1 were RGDLGLS, RGDMSRE,
DGLGRLV, and DRSPLSL. After three rounds of selection,
RGDLGLS and RGDMSRE were the dominant clones (Table 1).
Both peptides share the sequence motif RGDXXXX.
Selected AAV capsids efficiently transduce primary
murine breast cancer cells
To test whether the selected AAV capsid mutants allow for
improved gene delivery to primary PymT breast cancer cells, we
produced rAAV luciferase vectors displaying the selected peptides
RGDLGLS, RGDMSRE, and DGLGRLV for further analysis.
These vectors transduced primary PymT breast cancer cells up to
17.8-fold better than wild-type AAV-2 vectors, and up to 3.500-fold
better than vectors displaying an unselected random peptide
(VRRPRFW) (Figure 2A). In contrast, HeLa cervical cancer cells,
3T3 mouse fibroblasts and primary mouse hepatocytes were not
permissive for transduction with the selected capsid variants while
they could be efficiently transduced with wild-type AAV transduc-
tion (data not shown), suggesting target specificity of the selected
clones and supporting their use for targeting breast cancer cells in
vivo. These findings were further corroborated by experiments using
modified vectors harboring SR39, a derivative of the HSV-tk
suicide gene [45,51,52]. Primary PymT breast cancer cells
transduced by vectors with the RGDLGLS capsid insert showed
strong cytotoxic effects upon ganciclovir treatment, whereas cells
transduced with control vectors were almost resistant to ganciclovir
(Figure 2B). Taken together, these findings suggest RGDLGLS-
AAV as an interesting candidate for targeting therapeutic genes to
breast cancer cells and demonstrate that our novel Ad5-free, PCR-
based biopanning protocol allows for selection of targeted AAV
vectors from random AAV display peptide libraries.
We therefore investigated whether the capsid mutants selected
in vitro can target PymT breast tumors in vivo. AAV luciferase
vectors displaying the selected peptides RGDLGLS, RGDMSRE,
DGLGRLV, an unselected control peptide, or no peptide (wild-
type AAV), respectively, were injected intravenously into female
PymT mice bearing breast cancers. Analyses of reporter gene
expression in tumor tissue revealed that none of the vectors
mediated gene transduction in the tumor tissue (data not shown).
Kinetics of circulating AAV peptide library particles and
wild-type AAV are similar
Based on the negative finding above, we hypothesized that
selection under in vivo conditions is needed to enrich library clones
that are able to bind cellular receptors in tumors, penetrate the
tumor tissue and are internalized into tumor cells under
physiological circulation conditions after intravenous administra-
tion. But we suspected that our novel PCR-based selection of AAV
libraries may not be able to distinguish between library particles
successfully internalized into target cells, and non-homing particles
present in the circulation if the tissue is harvested too early after
injection. To minimize the amount of circulating AAV library
particles in our tissue samples at the time point of harvest, we
analyzed the kinetics of circulating AAV library particles.
Therefore, AAV were injected intravenously at 161010 vg per
mouse, blood samples were collected at various time points, and
the amount of circulating particles in the serum was quantified by
real-time PCR. Clearance rates were comparable in AAV library
particles and wild-type viruses (Figure 3). The amount of
circulating genomes decreased in a straight proportional manner.
We therefore decided to harvest tissues in AAV library selections
48 hours after virus administration.
In vivo selection of AAV display peptide libraries in tumor
tissue results in enrichment of distinct peptide inserts
Two technical approaches were chosen for AAV library
selections in vivo (Figure 1, pathways B and C). Secondary libraries
were produced and analyzed as for in vitro selections. Genomic
titers of selected libraries allowed for injection of 26108 vg per
mouse in selection rounds 2–4 (data not shown). After 4 rounds of
selection, sequencing revealed the enrichment of serine and
glycine-rich peptide motifs and repetition of several single clones.
In particular, the motifs GGLSGXS and ESGXXXX, and the
single clones EYRDSSG, QMSGGVA, EEPALRA, as well as
APTLGLS were enriched during ‘‘in vivo/ex vivo’’ selections
(Table 2). In a separate approach, we performed 2 further rounds
of ex vivo selection with libraries pre-selected for 2 rounds on PymT
cells in vitro (like in Figure 1, pathway A). Here, the only remaining
clone following the in vivo part of this selection displayed the
peptide DLGSARA (Table 2). During in vivo selections (Figure 1,
pathway C), the peptide motifs enriched during four rounds of
selection were XXSGVGS, GEARXXA, and SGNSGAA, as well
as SSGSGGA and ESGIWVA (Table 2). The clones SGNSGAA
and SSGSGGA shared the similar sequence pattern SSG or SGG,
respectively, which also occurred in the EYRDSSG and
QMSGGVA clones enriched during ex vivo selection. The motif
ESGXXXX was highly enriched in both in vivo/ex vivo and pure in
vivo selections. These data suggest that AAV library selection under
circulation conditions is feasible and causes enrichment of a
distinct pattern of displayed peptides after multiple rounds of
biopanning. Therefore, we decided to evaluate in vivo gene
transduction for all enriched clones.
Table 1. Peptides enriched after PCR-based in vitro selection (pathway A) of AAV peptide libraries on primary breast cancer cells
Peptide sequence a Charge pattern b Frequency in selection round
c
round 1 round 2 round 3
RGDLGLS +y-yyyx - 3/10 6/9
RGDMSRE +y-yx+- - 1/10 3/9
DGLGRLV -yyy+yy - 3/10 -
DRSPLSL -+xyyxy 1/6 2/10 -
asingle letter code; shared amino acid patterns are highlighted in colored letters
bcharge pattern of amino acid side chains: +, positively charged; 2 negatively charged; x, uncharged polar; y, nonpolar.
cobserved frequency relative to overall number of sequenced clones
doi:10.1371/journal.pone.0005122.t001
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Selected library-derived AAV transduce tumors in vivo
To assess whether the in vivo-selected AAV-2 vectors mediate
gene expression in tumor tissue in vivo, we produced luciferase
reporter vectors displaying the selected peptide sequences. All
vectors titers ranged between 861010 to 761011 vg/ml (data not
shown). Luciferase gene expression in the breast tumor tissue was
evaluated 8 days after intravenous injection in tumor-bearing
PymT mice in a screening experiment to assess which clones
should be investigated in detail. Five of the clones (GEARISA,
SGNSGAA, ESGLSQS, EYRDSSG, and DLGSARA) showed an
increased transduction of the breast tumor tissue compared to
wild-type AAV vectors, whereas unselected control vectors did not
mediate any gene expression (data not shown). We chose the most
promising vectors for further experiments in a larger group of
animals (n = 5 mice per clone). Following intravenous injection,
the selected clones transduced tumor tissue up to ,275-fold more
efficient compared to wild-type AAV vectors (Figure 4A). To
further investigate the specificity of selected AAV capsid mutants,
Figure 2. Vector capsids selected from random AAV display peptide libraries for targeted gene transfer in primary breast cancer
cells. A: Primary PymT breast cancer cells were transduced by recombinant AAV-2 luciferase reporter gene vectors displaying the selected capsid
peptide inserts RGDLGLS, RGDMSRE, or DGLGRLV, respectively. Capsids with no (wild-type) or random peptide insert (VRRPRFW) were used as
controls. Transduction efficiency was determined after 72 hours by luciferase assay. Luciferase activities are shown in relative light units (RLU) per
well. Data represent mean values6 standard deviation (SD) from one representative experiment (out of three) in triplicates (*** = p,0.001 compared
to wild-type and random insert controls). B: Breast cancer cell-targeted therapeutic suicide gene transfer using selected capsid mutants. Primary
PymT cells were transduced using rAAV-SR39 vectors displaying RGDLGLS or a randomly selected control peptide (VRRPRFW). Four days after
initiation of ganciclovir (GCV) treatment, cytotoxic effects were evaluated by MTT assay. Values are shown in % cytotoxicity (i.e., % killed cells).
Untreated and untransduced cells served as controls. Data represent mean values 6 standard error of the mean (SEM) from nine wells in three
independent experiments (*** = p,0.001 selected clone and treated cells vs. all controls).
doi:10.1371/journal.pone.0005122.g002
AAV In Vivo Library Panning
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luciferase expression in several control organs was evaluated
(Figure 4B). Moderate de-targeting from the liver by clone
ESGLSQS and the unselected control was observed, whereas
clones GEARISA and EYRDSSG transduced the liver in a
manner comparable to wild-type AAV. DLGSARA gene
transduction in liver tissue was significantly increased compared
to the unselected control vector. Further, we found a strongly
enhanced cardiac luciferase expression for all clones, being
statistically significant for GEARISA, EYRDSSG and
DLGSARA, and a weakly enhanced cardiac transduction of the
unselected control vector compared to wild-type AAV. In regard
to tissue specificity, the ESGLSQS clone had the most favorable
profile as it transduced tumor tissue but not the liver. However,
cardiac gene transduction was seen for this as for almost all the
other clones as well. Reproduction of in vivo gene transduction with
independent vector preparations for DLGSARA and ESGLSQS
precisely confirmed our results (data not shown).
In vivo selection of AAV capsids targeting lung tissue
To address the question whether the organ transduction pattern
of clones obtained by in vivo AAV library screenings depends on
the target tissue the library was selected for, we also selected AAV
libraries for preferential homing into lung tissue. The screening
was done along the lines of the tumor targeting approach (Figure 1,
pathway C). We varied the time of library circulation before tissue
harvest in the first round (5 minutes and 2 days, respectively) in
two independent approaches. For both selections, circulation time
was increased to 6 days in selection rounds 2–4. After 4 rounds of
in vivo selection for both approaches, sequencing of the peptide
insert of the AAV clones recovered from the lung revealed a
striking consensus sequence motif, PRSAD(D/L)(A/S) , which was
enriched independently in both selection procedures (Table 3).
These data show that in vivo selection of AAV libraries in vivo in
distinct tissues yields distinct peptide inserts, suggesting tissue
specificity of the selection process.
AAV clones displaying the PRSAD(D/L)(A/S) motif
transduce lung tissue in vivo after systemic
administration
Reporter gene vectors were made carrying the PRSTSDP and
PRSADLA peptides or controls and gene transduction in vivo was
evaluated. In a first step, we investigated whether the selected
AAV capsid variants home to lung tissue more efficiently than
AAV control vectors (wild-type or random insert capsids). Vectors
were administered intravenously, and DNA was recovered from
lung tissue after 8 days. Quantitative PCR of the CMV promoter
region of the vectors revealed an up to 63-fold higher yield for the
selected capsid variants compared to AAV-2 wild-type vectors and
up to 74-fold higher yield compared to random control insert
vectors (Figure 5A). Evaluation of luciferase expression in the lung
28 days after intravenous administration revealed a 35-fold and
233-fold increased transduction efficiency of PRSADLA and
PRSTSDP, respectively, compared to wild-type AAV (Figure 5B).
To determine the specificity of lung-targeted capsids, luciferase
expression in several control organs was evaluated. Both selected
clones showed higher gene transduction in liver, heart, kidney,
brain, and muscle, compared to unselected controls (Figure 5C),
suggesting that the cellular target bound by the selected vectors in
vivo is ubiquitously rather than lung-specifically expressed.
Figure 3. Kinetics of circulating AAV peptide library particles is similar to wild-type AAV. A random X7 peptide library or wild-type AAV-2
viruses were injected intravenously at 161010 vg per mouse. Blood samples were collected after indicated time points and the amount of circulating
viral particles in the serum was determined by real-time PCR. Data represent mean values from n=3 mice per group, analyzed in triplicates 6 SD.
doi:10.1371/journal.pone.0005122.g003
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Discussion
Vector targeting in vivo is of paramount importance in gene
therapy. For adeno-associated virus (AAV), this issue has been
addressed by the insertion of peptide ligands into the vector capsid
[6,7,8,9,10,11,12] or by exploiting the diversity of the various
capsid serotypes [4,5]. Despite considerable progress in this field,
the availability of tissue-directed vectors for in vivo use is very
limited, especially if delivered intravenously.
The screening of random AAV display peptide libraries is an
innovative tool to select for vectors efficiently transducing any cell
type of interest and has been described and validated for various cell
types in vitro [14,33,34,35,36]. Most of the vectors described in these
studies, however, have not been validated for in vivo use.
In our studies, library-derived vector capsids (displaying
RGDLGLS, DGLGRLV) selected on primary murine breast
cancer cells in vitro transduce the cell type they were selected on
with high efficiency but fail to mediate breast cancer tissue
directed gene transduction after systemic administration. As a
consequence, we performed screenings of AAV libraries in vivo
over multiple selection rounds after tail vein injection via the blood
stream, using tumor and lung as target tissues. Several peptide
clones were enriched in tumors and a clear-cut peptide sequence
motif was recovered from the lung. While we achieved
transduction of the target tissue by the selected vectors, we failed
to achieve truly tissue-specific transgene expression. Therefore,
except for liver transduction, most of our selected vectors have a
tropism that is expanded to rather than specific for the tissue of
interest compared to wild-type AAV-2. This may be due to several
reasons: 1) the lack of tissue-specific receptors; 2) the expression of
receptors conferring optimum transduction in several tissues, so
capsids targeting receptors that are tissue-specific, but less efficient
for transduction are not enriched; 3) superordinate (not receptor-
dependent) factors influencing the selection process such as
endothelial barriers, blood-derived factors, or extracellular matrix
interactions. The first reason can be virtually excluded based on
the overwhelming success rate of in vivo tissue targeting using
phage display libraries [16,17,18,19,20,21,22,23,24,25,26,27,
28,29,30,31,32]. Regarding the expression of non-tissue-specific
receptors that are compatible with optimized AAV transduction,
we think that two factors may play a role. Some of the selected
peptides mediated transduction of several tissues with a clone-
dependent transduction pattern, suggesting that the tropism is
mediated by the targeting peptide. Especially for the lung-
transducing vectors, the broad-spectrum tropism may also be
due to the mechanism of library selection. Upon intravenous
injection, virus capsids with optimized in vivo binding behavior may
have been enriched in the lung irrespective of tissue specificity due
to the first-pass effect after intravenous injection. These vectors
may well be cell type-specific but not tissue-specific. They may be
Table 2. Peptides enriched in tumor tissue after selection for tumor-homing AAV
Selection pathway Peptide a Charge pattern b Frequency in selection round
c
round 1 round 2 round 3 round 4
Pathway B GGLSGVS yyxxyyx -/6 -/7 1/22 7/41
GGLSGDS yyxxy-x -/6 -/7 -/22 1/41
GSVSGSA yxyxyxy -/6 -/7 -/22 1/41
EYRDSSG -y+-xxy -/6 -/7 -/22 7/41
QMSGGVA xyxyyyy -/6 -/7 -/22 1/41
ESGLSQS -xyyxxx -/6 1/7 1/22 2/41
ESGIWVA -xyyyyy -/6 -/7 1/22 2/41
EEPALRA --yyy+y -/6 -/7 -/22 4/41
APTLGSP yyxyyxy -/6 1/7 -/22 13/41
Pathway B d RGDLGLS +y-yyyx 5/16 -/10
DLGSARA -yyxy+y 2/16 10/10
DGLGRLV -yyy+yy 6/16 -/10
DLRGLAS -y+yyyx 1/16 -/10
DRSPLSL -+xyyxy 1/16 -/10
Pathway C AISGVGS yyxyyyx -/6 1/15 2/24 2/32
DRSGVGS -+xyyyx -/6 1/15 4/24 2/32
SISGVGS xyxyyyx -/6 -/15 -/24 1/32
SEGRSGV x-y+xyy -/6 -/15 -/24 1/32
GEARSRA y-y+x+y -/6 -/15 -/24 1/32
GEARISA y-y+yxy -/6 -/15 2/24 7/32
SGNSGAA xyxxyyy -/6 1/15 4/24 8/32
SSGSGGA xxyxyyy -/6 -/15 2/24 2/32
ESGIWVA -xyyyyy -/6 -/15 -/24 2/32
asingle letter code; only peptides occurring repetitively or sharing common sequence motifs are shown; shared amino acid patterns are highlighted in colored letters
bcharge pattern of amino acid side chains: +, positively charged; 2 negatively charged; x, uncharged polar; y, nonpolar.
cobserved frequency relative to overall number of sequenced clones
dpathway B subsequent to 2 rounds of in vitro selection as in pathway A
doi:10.1371/journal.pone.0005122.t002
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directed to endothelia in general, which is underlined by the fact
that a similar capsid mutant (PRSVTVP) has been previously
selected on primary endothelial cells in vitro [14]. This emphasizes
the importance of the simultaneous negative selection in library
screenings in vivo that can be achieved in tissues other than the
lung. If the lung is the target of a screening, additional negative
selection steps on endothelial cells prior to in vivo selection might
alleviate some of the specificity challenges encountered in our
targeting experiments. The second factor influencing the extended
but unspecific tropism relates to the remarkable observation that
as long as our selected vectors conferred any transgene expression
in vivo, it invariably also occurred in the heart in addition to the
target tissue. Heart expression of these vectors was even stronger
than in wild-type AAV vectors. This is congruent with previous
studies describing increased heart transduction upon modification
of the VP3 region R484E/R588E [13] and peptide insertions at
Figure 4. Gene delivery by AAV capsid mutants selected for breast cancer transduction in vivo. AAV luciferase vectors displaying selected
peptides or controls (wild-type or VRRPRFW) were injected intravenously into female PymT tumor-bearing mice. After 8 d, representative tissues were
harvested and luciferase activities were determined in individual tissues as relative light units (RLU) per mg protein. A: In vivo transduction of tumor
tissue in PymT transgenic FVB mice by selected AAV mutants. Bars indicate the median, n = 5 mice per group. * p,0.05 targeted vectors vs. wild-type.
# p,0.05 targeted vectors vs. random insert control. B: In vivo transduction of various non-cancerous tissues in PymT transgenic FVB mice by tumor-
selected AAV mutants. The dotted line indicates the threshold beyond which luciferase expression data could be reliably delineated from background
signal. Data represent mean values 6 SEM, n = 5 mice per group. * p,0.05; ** p,0.01 targeted vectors vs. wild-type AAV-2. # p,0.05; ## p,0.01
targeted vectors vs. random insert control.
doi:10.1371/journal.pone.0005122.g004
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position R588 [14]. Our results in conjunction with the previously
published data suggest that cardiac gene transduction may be
mediated by a redistribution effect resulting from ablation of the
endogenous tropism of the vector [13,14], but clearly is also
mediated by the design of the peptide insert as it varied from clone
to clone. This might indicate that a capsid region close to the
library insert at position R588 contributes to this tropism and that
it may therefore be independent of the selected peptide sequence
as such. Yet, biodistribution studies have not revealed increased
heart homing by peptide insertion in this region [10,11], which
might in part be attributable to, or at least influenced by, a slightly
differing insertion site (position N587 instead of R588). These
findings re-emphasize that the gene expression profile mediated by
a gene vector is not solely reflected by its biodistribution profile but
also depends on factors like intracellular processing, promoter
activity and vector clearance mechanisms.
Perabo et al. recently described that peptides containing a net
negative charge and inserted at the AAV capsid position 587 are
prone to confer a heparin sulfate proteoglycan non-binding
phenotype which correlates with liver and spleen de-targeting in
mice [15]. However, in our screenings we also isolated negatively
charged peptides such as EYRDSSG which retained strong liver
transduction. This may suggest that such selected capsid variants
in our study indeed do not bind to heparin sulfate but rather to a
ubiquitously expressed alternative receptor. In turn, we also
isolated capsid mutants such as ESGLSQS which de-target from
the liver compared to wild-type AAV, contradicting the assump-
tion that additional mutations outside of the peptide insertion site
at position 588 may be required to achieve this de-targeting effect.
Despite its obvious limitations, in vivo screening of AAV-2 libraries
allows for selection of vectors with an extended tropism towards the
tissue of interest. Vectors targeting the endothelial cell layer in vivo
might be used to deliver anti-angiogenic genes such as endostatin in
order to block neovascularization and tumor growth [53].
Furthermore, vectors transducing various organs might be useful
when expression in tissues other than the primary target is desirable
or uncritical as it has been performed by expression of the SOD
gene delivered by adenovirus to protect lung tissue against
radiation-induced fibrosis [54]. Compared to AAV vectors like
AAV6 transducing lung tissue after nasal aspiration [55], vectors
like the ones presented here which transduce lung tissue after
intravenous injection, may also target other cell types such as lung
endothelia and may therefore be considered as a valuable addition
to the arsenal of lung-directed gene vectors. Finally, the tumor-
directed vectors displaying the ESGLSQS peptide that mediates
AAV transduction of breast cancer tissue in vivo and AAV de-
targeting from the liver may further be optimized by using tumor
specific expression systems such as the hTERT promoter [56,57].
In previous work on AAV libraries, internalized virus particles
were amplified by adenoviral delivery of helper proteins
[14,33,34,35]. However, the pathogenicity of adenovirus impedes
the use of this strategy for in vivo selections, especially if it has to be
administered systemically. Furthermore, the helper-dependent
selection requires a near to complete adenoviral infection of the
target tissue in order to maximize the amount of clones that can be
amplified. Using currently available helper viruses, this can not be
achieved in all organs and tissues in vivo, particularly in light of the
fact that many target tissues or cell types are not susceptible to
adenoviral infection after systemic administration. In addition, it is
not clear (and at least in the tumor tissue used in our study very
questionable) if AAV can replicate in mouse tissue efficiently. Our
novel selection method addresses these points. Relevant parts of
the genomes of tissue-targeted library viruses are amplified via
nested PCR. We distinguished between three alternative selection
pathways, all of which are based on the amplification and
enrichment of tissue-homed AAV library particles by PCR during
the selection process. Pathway A is a cell-based in vitro selection
approach in which genomes of internalized library viruses are
amplified while non-internalized viral particles are eliminated.
Although our PCR selection protocol does not exclusively force
the selection for AAV capsids that mediate gene expression, we
demonstrate the functionality of this technical approach in that
clones sharing a common peptide motif (RGDXXXX) were
recovered by screening on primary murine breast cancer cells and
conferred efficient transduction of these cells, even in a cytotoxic
suicide gene transfer approach. Similar peptide motifs have been
selected on PC3 prostate carcinoma cells [34] and M07e human
leukemic megakaryocytic cells [33] by adenovirus-based selection.
Incorporation of the RGD sequence into the viral capsid can
target the vector to integrins, which are widely expressed on
several cell types [6,8,58]. This suggests that AAV clones with an
RGD-containing peptide insert might target via the integrin class
of receptors [59]. The RGD integrin recognition sequence is also
present in the so-called RGD4C-peptide which binds avß3 or
avß5 integrins. This peptide homes to tumors in vivo after systemic
administration and has therefore been widely used to target
cellular integrins expressed in the tumor tissue of xenograft mouse
models [17,60,45,61]. It may therefore be tempting to speculate
that the RGD-displaying AAV clones presented here might, like
the RGD4C-peptide, also target tumor cells via the aV class of
integrins. However, we consider this unlikely because the clones
did not show preferential homing to tumor tissue in vivo and RGD
as a tripeptide sequence by no means specifically binds to this class
but also to other classes of integrins. In fact, 12 of the 20 currently
known integrins recognize a certain RGD-containing sequence as
their ligand [59].
Pathways B and C aimed at selection of virus capsid variants
after systemic administration of AAV libraries in vivo. These
Table 3. Peptides enriched in lung tissue during in vivo
selection for lung-homing AAV after four rounds of selection
Selection pathway Peptide a Charge pattern b















Consensus motif P R S A D (D/L) (
A/S)
asingle letter code; shared amino acid patterns are highlighted in red letters
bcharge pattern of amino acid side chains: +, positively charged; 2 negatively
charged; x, uncharged polar; y, nonpolar.
doi:10.1371/journal.pone.0005122.t003
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pathways take into account several hurdles that limit viral receptor
targeting under in vivo conditions. Thus, tissue homing particles
with weak or unspecific binding capacities toward their targets are
eliminated by host clearance mechanisms or by homing to other
tissues, although the screening process does not guarantee that the
selected clones confer gene expression in addition of homing to the
target tissue. Upon using selection pathways A, B, or C for tumor
targeting, the enriched peptide sequences varied depending on the
respective selection pathway, indicating that the most suitable
screening conditions may have to be evaluated for each individual
target tissue.
Compared to the previous work in which AAV libraries were
selected in vitro on various target cells, these results are a significant
step forward and profoundly expand our knowledge on the
mechanisms involved in the in vivo gene transduction of vectors
derived from biopanning of AAV peptide libraries. In addition,
they overcome some of the limitations observed in a recent report
by Grimm et al. [37]. In this pivotal work, AAV libraries were
selected in vivo based on topical application to the airways (as
opposed to systemic administration like in our study). Conse-
quently, while two selected capsid mutants (NSSRDLG,
MVNNFEW) in this study mediated gene transfer to certain cell
types in the lung tissue after administration by inhalation, they
failed to mediate vector retargeting after systemic administration.
Interestingly, the NSSRDLG peptide insert described in this study
was also described in previous studies on other cell types [14,37]
but also overlaps with the DLGSARA insert isolated from breast
cancer tissue in the work presented here. Yet, both peptides
probably bind to different receptors as the in vivo tropism seems to
be very different which indicates that, at least for AAV, the whole
peptide sequence rather than parts of a sequence motif has to be
considered to evaluate its tropism.
Figure 5. Targeting of AAV capsid mutants selected on murine lung tissue in vivo. AAV luciferase vectors displaying selected or control
capsids (wild-type or random insert VRRPRFW) were injected intravenously into female FVB mice. Tissue was harvested after 8 or 28 d, respectively,
and processed as indicated. A: Evaluation of lung homing. Lung tissue was harvested 8 days after vector injection and the amount of AAV genomes
was determined by quantitative PCR. Data represent mean values from n=3 mice per group, analyzed in triplicates 6 SD. B: In vivo lung gene
transfer by selected AAV after intravenous injection. Lung tissue was harvested 28 days after vector injection, and luciferase activity was determined
as relative light units (RLU) per mg protein. Bars indicate the median value, n = 5 mice per group (** = p,0.001 targeted vectors vs. wild-type and
random insert control). C: In vivo transduction of various tissues in mice by AAV library mutants selected for lung transduction. Tissues were
harvested and luciferase activity was determined as in 5B. The dotted line indicates the threshold beyond which luciferase expression data could be
reliably delineated from background signal. Data represent mean values 6 SEM, n= 5 mice per group. * p,0.05; ** p,0.01 targeted vectors vs. wild-
type AAV-2. # p,0.05; ## p,0.01 targeted vectors vs. random insert control.
doi:10.1371/journal.pone.0005122.g005
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In addition, the two selections (in Grimm et al. [37] and in our
study) were done in a different AAV backbone context. Of note, in
the work by Grimm et al. [37], the diversity of recovered AAV after
two rounds of selection was restricted to one clone, presumably
due to inefficient amplification and rescue of clones using
adenoviral helper functions. Such outcome might change upon
applying our novel PCR amplification protocol. Furthermore,
novel AAV library principles like sequence evolution by error-
prone PCR [62] and DNA shuffling [63] might enhance specificity
and efficiency if used for in vivo selection.
This is the first report of in vivo biopanning with a systemically
administered random AAV peptide library over multiple selection
rounds. We show that vectors displaying in vivo-selected peptides
have a significantly improved transduction profile in breast cancer
or lung tissues after systemic administration. These findings
demonstrate the superiority of AAV clones selected in vivo over
clones selected in vitro, as long as in vivo transduction is required.
Unintended cardiac transduction by selected clones remains the
major limitation to be addressed in subsequent studies, e.g., by
further functional mapping of the capsid. Our findings broaden
the understanding of AAV transduction profiles in vivo, the
functionality of random AAV display peptide libraries and, even
beyond the specific targets tumor and lung, are an important step
in the development of targeted AAV gene vectors.
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